Stocktoria
Entera Bio Ltd. ENTX
Entera Bio Ltd. (ENTX) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $42,000 at a -27235.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ENTX | Entera Bio Ltd. | 2/9 | — | — | — |
| INMB | Inmune Bio, Inc. | 3/9 | — | — | — |
| SNTI | Senti Biosciences Holdings, Inc. | 2/9 | — | — | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 4/9 | -1.04 | — | — |
| SRRK | Scholar Rock Holding Corp | 1/9 | -9.91 | — | -100% |
| SABS | SAB Biotherapeutics, Inc. | 3/9 | 6.9 | 21.9 | — |
| RVMD | Revolution Medicines, Inc. | 1/9 | -0.01 | — | — |
About Entera Bio Ltd.
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
FAQ
Is ENTX financially healthy?
Entera Bio Ltd.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does ENTX pay a dividend?
No, Entera Bio Ltd. does not currently pay a dividend.
How profitable is ENTX?
In FY2025, Entera Bio Ltd. had a net margin of -27235.7% and a return on equity of -87.3%.
Is ENTX overvalued or undervalued?
Entera Bio Ltd. trades at about 11.2× trailing earnings — above its 10-year norm (10-year range 2.0×–8.8×, median 4.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ENTX?
The average Wall-Street price target for Entera Bio Ltd. is $9.00, about 221.4% above the recent price, from 1 analysts (consensus: strong buy).
Is ENTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Entera Bio Ltd.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.